Last reviewed · How we verify
Bronchodilators
Bronchodilators is a Small molecule drug developed by University of Rome Tor Vergata. It is currently in Phase 2 development. Also known as: Albuterol, Tiotropium bromide, ipratropium bromide; salbutamol sulfate, Broncholytic.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bronchodilators |
|---|---|
| Also known as | Albuterol, Tiotropium bromide, ipratropium bromide; salbutamol sulfate, Broncholytic |
| Sponsor | University of Rome Tor Vergata |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AI-Powered Sound Analysis for COPD Screening
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years (EARLY_PHASE1)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Impact of Multi-Component Interventions on High Risk COPD Population (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bronchodilators CI brief — competitive landscape report
- Bronchodilators updates RSS · CI watch RSS
- University of Rome Tor Vergata portfolio CI
Frequently asked questions about Bronchodilators
What is Bronchodilators?
Who makes Bronchodilators?
Is Bronchodilators also known as anything else?
What development phase is Bronchodilators in?
Related
- Manufacturer: University of Rome Tor Vergata — full pipeline
- Therapeutic area: All drugs in Respiratory
- Also known as: Albuterol, Tiotropium bromide, ipratropium bromide; salbutamol sulfate, Broncholytic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing